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Background: Nanomaterials have unique advantages in controlling stem cell function due to 
their biomimetic characteristics and special biological and mechanical properties. Controlling 
adhesion and differentiation of stem cells is critical for tissue regeneration.
Methods: This in vitro study investigated the effects of nano-hydroxyapatite, nano-hydroxyapatite-
polylactide-co-glycolide (PLGA) composites, and a bone morphogenetic protein (BMP-7)-
derived short peptide (DIF-7c) on osteogenic differentiation of human mesenchymal stem cells 
(MSC). The peptide was chemically functionalized onto nano-hydroxyapatite, incorporated 
into a nanophase hydroxyapatite-PLGA composite or PLGA control, or directly injected into 
culture media.
Results: Unlike the PLGA control, the nano-hydroxyapatite-PLGA composites promoted 
adhesion of human MSC. Importantly, nano-hydroxyapatite and nano-hydroxyapatite-PLGA 
composites promoted osteogenic differentiation of human MSCs, comparable with direct 
injection of the DIF-7c peptide into culture media.
Conclusion: Nano-hydroxyapatite and nano-hydroxyapatite-PLGA composites provide a 
promising alternative in directing the adhesion and differentiation of human MSC. These 
nanocomposites should be studied further to clarify their effects on MSC functions and bone 
remodeling in vivo, eventually translating to clinical applications.
Keywords: human mesenchymal stem cells, osteogenesis, stem cell differentiation, bone 
morphogenetic protein, peptide delivery, nanocomposites
Introduction
Nanomaterials for bone regeneration
Nanomaterials have demonstrated promising capabilities in stimulating cell function 
and enhancing tissue regeneration due to their biomimetic features and unique 
physicochemical, mechanical, and biological properties. Nanomaterials can be 
composed of metals, ceramics, polymers, and composites, with at least one dimension 
less than 100 nm. Natural bone is a nanocomposite, which contains nanoscale 
building blocks comprising mainly collagen fibrils and mineral hydroxyapatite 
plates. Biodegradable and bioactive nanocomposites are attractive for orthopedic and 
maxillofacial applications due to their advantageous properties for better bone tissue 
regeneration. Nanocomposites not only provide better surface and physicochemical 
properties for osteoblast attachment and long-term function (collagen and calcium 
synthesis), but also have better mechanical properties (elastic modulus and strength) 
for certain load-bearing conditions.1–4
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Nanophase hydroxyapatite, a derivative of calcium 
phosphate, is chemically and structurally similar to natural 
bone minerals and is biodegradable. Additionally, increased 
new bone formation has been observed as early as 2 weeks on 
nano-hydroxyapatite-coated tantalum scaffolds compared with 
micron-sized hydroxyapatite-coated scaffolds and uncoated 
scaffolds when implanted into rat calvarial bone.5 Polylactide-
co-glycolide (PLGA) has been approved by the US Food and 
Drug Administration for certain human clinical applications 
and has been extensively studied for drug delivery.6–8 As a 
copolymer of polylactic acid and polyglycolic acid, PLGA is 
a biodegradable polyester, the variable molecular weight and 
composition of which can be rationally designed to control 
the release kinetics of encapsulated therapeutic agents. The 
incorporation of osteoconductive nano-hydroxyapatite into 
PLGA can improve the mechanical properties and moderate 
the degradation rate of the scaffold.9–11 Specifically, nano-
hydroxyapatite slows the degradation of PLGA.   Further, 
nano-hydroxyapatite-PLGA scaffolds support greater rabbit 
mesenchymal stem cell (MSC) growth and alkaline phos-
phatase activity than PLGA scaffolds.12 The addition of nano-
hydroxyapatite particles into the PLGA scaffold confers better 
biological, mechanical, and degradation properties.
Bone morphogenetic proteins and 
functional peptides for bone regeneration
Bone morphogenetic proteins (BMPs), including rhBMP-2 
and BMP-7, are the most potent growth factors for enhanc-
ing bone formation.13–16 BMPs have several hundred amino 
acids, approximately 2–3 nm in size, depending on their 
conformation. The complex secondary structure of BMPs 
renders them prone to degradation, and they tend to lose their 
bioactivity quickly in aqueous physiological conditions. A 
short functional peptide derived from the active regions of 
the BMP has the potential to increase the efficacy of BMP 
delivery. Short peptides can attach to drug carriers more 
efficiently due to their small size while still maintaining 
functionality and bioactivity. Chen and Webster investigated 
three short peptides derived from the bioactive regions of 
BMP-7.17 These three peptides were composed of 10 amino 
acids and were designated as peptide A (SNVILKKYRN), 
B (KPCCAPTQLN), and C (AISVLYFDDS). The results 
showed that peptide B increased osteoblast proliferation, 
while peptides A and C promoted osteoblast differentiation 
(eg, mineralization).17 In this study, peptide C was chosen as 
the model peptide because of its ability to promote osteoblast 
differentiation and was slightly modified for ease of chemical 
functionalization. The BMP-7-derived short peptide was 
either directly injected into cell culture media or delivered 
by nano-hydroxyapatite, PLGA, or nanocomposites to study 
the effects on human MSC function.
Human MSC for bone regeneration
Human MSCs are desirable cells for bone tissue regenera-
tion due to their capability of self-renewal and potential for 
osteogenic differentiation.18,19 Specific bioactive growth 
factors, nutrients, and environmental cues can direct human 
MSC differentiation into the mesodermal lineage, including 
osteoblasts, chondrocytes, and adipocytes.20 BMP-2 and 
BMP-7 can induce osteoblast-like genes and matrix miner-
alization in primary human MSC culture.21 Importantly, the 
biological and mechanical properties of scaffold materials 
play important roles in the attachment and differentiation of 
human MSC.
The objective of this study is to investigate the effects 
of nano-hydroxyapatite, PLGA, and nano-hydroxyapatite-
PLGA composites on bone marrow-derived human MSC 
functions in comparison with a short functional peptide of 
BMP-7.
Materials and methods
Synthesis of nanocrystalline 
hydroxyapatite
Nanophase hydroxyapatite was synthesized by wet chemistry 
precipitation followed by hydrothermal treatment to gain 
control over desirable grain sizes and crystallinities. Briefly, 
hydroxyapatite was precipitated by mixing solutions of 
calcium nitrate and diammonium hydrogen phosphate in 
an alkaline pH region.22 Specifically, a 1 M calcium nitrate 
solution and a 0.6 M ammonium phosphate solution were 
prepared by dissolving their respective solid state powders in 
deionized water separately. The ammonium phosphate solu-
tion produced was mixed with deionized water, which was 
adjusted to pH 10 by ammonium hydroxide. The premade 
1 M calcium nitrate solution was then added into the mixture 
of ammonium phosphate and ammonium hydroxide at a 
rate of 3.6 mL/minute. Precipitation occurred as soon as the 
calcium nitrate was added. Chemically, the hydroxyapatite 
precipitation occurred through the reaction:
10Ca(NO3)2 + 6(NH4)2HPO4 + 8NH4OH 
  → Ca10(PO4)6(OH)2 + 6H2O + 20NH4NO3  (1)
Precipitation was continued for 10 minutes at room tem-
perature with constant stirring. The supernatant was collected, 
centrifuged (Eppendorf centrifuge, model 5810 R) to reduce 
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75% of the solution volume, and placed into a 125 mL Teflon 
liner (Parr Instruments, Moline, IL). The Teflon liner was 
sealed tightly in a Parr 4748 acid   digestion bomb (Parr Instru-
ments) and treated hydrothermally at 200°C for 20 hours to 
obtain nanocrystalline hydroxyapatite. Hydrothermal treat-
ment has a great advantage for preparing a stoichiometric, 
ultrafine hydroxyapatite powder with a homogeneous shape 
and size distribution due to higher than atmospheric applied 
pressures.23,24 After hydrothermal treatment, the nano-
hydroxyapatite particles were rinsed with deionized water 
and dried in an oven at 80°C for 12 hours.
The size and morphology of the nano-hydroxyapatite 
  particles have been previously characterized using field 
emission scanning electron microscopy. Specifically, 
nano-hydroxyapatite had an average particle size of 36 nm 
as determined by image analysis of scanning electron 
micrographs.22,25 The calcium to phosphate ratio of nano-
hydroxyapatite was 1.67 according to energy dispersive 
x-ray analysis.25 X-ray diffraction confirmed that the nano-
hydroxyapatite was   crystalline.26 A full characterization of 
nano-hydroxyapatite has been published previously.22,25,26
Design and synthesis of model peptide 
derived from BMP-7
Peptide C (AISVLYFDDS) derived from BMP-7 was modi-
fied at its N-terminal with a cysteine-containing spacer to 
ease chemical conjugation onto the nano-hydroxyapatite 
particles using aminosilane chemistry, followed by a 
maleimide cross-linker molecule. In this study, the peptide 
with a 12 amino-acid sequence of CKAISVLYFDDS was 
used as the model peptide and called DIF-7c. The peptide 
DIF-7c was obtained as carboxyl terminal acids to more than 
98.2% purity according to the high-pressure liquid chroma-
tography profile provided by the manufacturer (GenScript 
Corporation, Piscataway, NJ). The molecular weight of the 
peptide DIF-7c was 1360.56 g/mol.
Immobilization of peptide using 
aminosilane chemistry
The challenges of peptide delivery lie in efficient loading and 
controlled release. For peptide loading, nano-hydroxyapatite 
was functionalized by aminosilane chemistry under dry 
conditions to avoid surface contamination and, thus, ensure 
stability of the peptide.26,27 Briefly, nano-hydroxyapatite was 
first silanized in 3-aminopropyltriethoxysilane in anhydrous 
hexane. Second, for substituting a hetero-bifunctional cross-
linker for the terminal amine, the silanized nano-hydroxyapatite 
was coupled with N-succinimidyl-3-maleimido propionate 
(also  called  3-maleimidopropionic  acid  N-  hydroxysuccinimide 
ester, Sigma, St Louis, MO) in anhydrous N,N-dimethylfor-
mamide. Third, the peptide DIF-7c was immobilized onto 
nano-hydroxyapatite in anhydrous dimethylformamide 
through a reaction between the outer maleimide group 
with the thiol group of cysteine present in the terminal of 
DIF-7c. The nano-hydroxyapatite and the peptide DIF-7c 
conjugates bonded by aminosilane chemistry were called 
hydroxyapatite-Ps.
Fabrication of nanocomposites and 
control scaffolds
PLGA  pellets  were  purchased  from  Polysciences 
  (Warrington, PA) and fabricated into a solid scaffold using 
the solvent casting method. PLGA pellets had a 50/50 wt% 
polylactic/glycolide ratio, a molecular weight of 100,000–
120,000 g/mol, an intrinsic viscosity of 66–80 cm3/g, 
a polydispersity of 1.8, a density of 1.8 g/cm3, and a glass 
transition temperature of 45°C–50°C.2 For the hydroxyapa-
tite-PLGA nanocomposites, nanocrystalline hydroxyapatite 
(average particle size 36 nm) was added to the PLGA solu-
tion to give a 30:70 ceramic to polymer weight ratio. The 
composite mixture was sonicated for 10 minutes using a 
Misonix 3000 sonicator (Misonix Inc, New York) with its 
microtip immersed in the mixture. After sonication, the 
composite suspension was cast into a Teflon mold, evapo-
rated in air at room temperature for 24 hours, and dried in a 
vacuum chamber at room temperature for 48 hours. For the 
peptide-loaded nanocomposites (hydroxyapatite-Ps-PLGA), 
hydroxyapatite-Ps was dispersed in PLGA using a similar 
method as for hydroxyapatite-PLGA nanocomposites.
To fabricate the PLGA scaffold with peptide (PLGA-P) 
as a control, the peptide DIF-7c was dispersed directly in 
PLGA matrix using the solvent casting method. The amount 
of peptide dispersed in PLGA was calculated to be the same 
as the amount used for hydroxyapatite-Ps preparation.
All the nanocomposite and PLGA scaffolds were cut 
into 1 cm × 1 cm squares for use in the material charac-
terization and in vitro studies. The hydroxyapatite-PLGA 
and hydroxyapatite-Ps-PLGA nanocomposites had been 
previously characterized using a field emission scanning 
electron microscope, as shown in Figure 1.2,25
In vitro functions of human MSC
Stem cell adhesion and morphology
Human MSCs (Poietics® PT2501, Lonza, Walkersville, MD) 
were thawed and cultured in MSC growth medium (Lonza) 
under standard cell culture conditions, ie, a sterile, 37°C, 
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humidified, 5% CO2/95% air environment. MSC growth 
medium is composed of MSC basal medium (Lonza) plus 
MSC growth supplements, L-glutamine, and GA-1000 
(aqueous solution of gentamicin sulfate and amphotericin B), 
all from Lonza. The human MSCs were harvested from the 
posterior iliac crest of the pelvic bone of healthy volunteers 
according to the Lonza data sheet. Stem cells at the second 
passage were used for all the cell culture experiments.
All scaffolds of nanocomposites, peptide-loaded nano-
composites, and controls were placed in 12-well tissue culture 
plates (Corning Inc, Lowell, MA), sterilized under ultra-
violet radiation, and then rinsed three times with sterilized 
phosphate-buffered saline (containing 8 g NaCl, 0.2 g KCl, 
1.5 g Na2HPO4, and 0.2 g KH2PO4 in 1000 mL of deionized 
water adjusted to a pH of 7.4; all chemicals from Sigma). 
For the bioactive glass control, Thermanox® glass coverslips 
(Fisher Scientific, Barrington IL) surface-treated for cell 
culture were utilized. Human MSCs (second passage) were 
seeded at a density of 5000 cells/cm2 onto the scaffolds of 
interest and were then incubated in the MSC growth media 
under standard cell culture conditions for 6 days. After that 
time period, nonadherent cells were removed by rinsing with 
phosphate-buffered saline, and adherent cells were then fixed 
with formaldehyde (Fisher Scientific) and stained with DAPI 
and Alex Fluor® 488 (Invitrogen, Carlsbad, CA). The cell 
nuclei and cytoskeleton were visualized under a fluorescence 
microscope (Leica DM5500B upright) and recorded by an 
attached digital camera. Cells that adhered onto the surface 
of specimens were counted manually and confirmed using 
Image J software. Cell adhesion density was calculated as the 
average number of cells per centimeter squared. All samples 
were tested in triplicate.
Stem cell osteogenic differentiation
The human MSCs from Lonza were cultured until the second 
passage and seeded at a density of 5000 cells/cm2 in MSC 
growth media into 12-well culture plates with the scaffolds 
of interest and the controls as listed in Table 1. For the first 
6 days, cells were cultured in MSC growth media. After that, 
the cells were cultured in MSC osteogenic induction media 
to induce osteogenesis. The total length of cell   culture was 
40 days and the media were changed every 3 days. Osteogenic 
A B
200 nm
Figure 1 Scanning electron micrographs of (A) HA-PLgA (well-dispersed nano-hydroxyapatite in PLgA composite), (B) nano-HA-Ps-PLgA (HA-PLgA nanocomposite with 
chemically immobilized DIF-7c peptide). Original magnification 100,000×.
Notes: Magnification bars are 200 nm. A is adapted from Liu and Webster25 and B is adapted from Liu and Webster2 with permission of the respective publishers.
Abbreviations: HA, hydroxyapatite; PLgA, polylactide-co-glycolide; DIF-7c, bone morphogenetic protein (BMP-7)-derived short peptide; P, peptide; Ps, peptide loaded by 
aminosilane chemistry.
Table 1 Osteogenic differentiation of human mesenchymal stem cells was studied on the scaffolds and controls as listed below
Label Abbreviation Description
Nanocomposite 1 
2
HA-Ps-PLgA 
HA-PLgA
Nano-HA-PLgA composites loaded with peptide using aminosilane chemistry 
Nano-HA-PLgA without peptide
Nanophase HA 3 
4
HA-Ps 
HA
Nano-HA loaded with peptide using aminosilane chemistry 
Nano-HA without peptide
Polymer control 5 
6
PLgA-P 
PLgA
PLgA scaffold loaded with peptide 
PLgA scaffold without peptide
Peptide control 7 DIF-7c The DIF-7c peptide was directly injected into the cell culture media
Reference 8 
9
glass 
PSTC
Thermanox® surface treated borosilicate glass coverslip 
Polystyrene tissue culture plate
Abbreviations: HA, hydroxyapatite; PLgA, polylactide-co-glycolide; DIF-7c, bone morphogenetic protein (BMP-7)-derived short peptide; P, peptide; Ps, peptide loaded by 
aminosilane chemistry.
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induction media is composed of human MSC osteogenic 
basal media with dexamethasone, L-glutamine, ascorbate, 
penicillin/streptomycin, mesenchymal cell growth supple-
ment, and β-glycerophosphate (Lonza). At the end of the 
prescribed time period, the human MSCs were lysed using 
three freeze-thaw cycles in distilled water. Alkaline phos-
phatase activity and calcium deposition in the supernatant 
were determined according to standard protocols as described 
below. All experiments were run in triplicate and repeated at 
three separate times.
Alkaline phosphatase is an enzyme, the production of 
which signifies increased osteogenic differentiation of human 
MSC.28 An alkaline phosphatase assay kit   (QuantiChromTM, 
DALP-250, BioAssay Systems, Hayward, CA) was used to 
determine alkaline phosphatase activity in the cell lysates 
prepared as described above. Briefly, aliquots of 50 µL 
cell lysates were mixed with a 150 µL working solution 
of magnesium acetate and p-nitrophenyl phosphate in 
assay buffer. Then, the reaction was read at time = 0 and 
time = 4 minutes using a spectrophotometer (Spectra MAX 
190, Molecular Devices, San Jose, CA) at 405 nm. Alkaline 
phosphatase activity of the samples (IU/L) was calculated 
using the equation established in the assay data sheet.
The ultimate indicator of human MSC differentiation is 
calcium deposition, which was quantified using a commercial 
calcium assay kit (QuantiChromTM, DICA-500, BioAssay 
Systems). Briefly, calcium-containing supernatant from 
human MSC culture was mixed with the working reagent, 
incubated for 3 minutes, and the optical density was read 
at 612 nm using a spectrophotometer (Spectra MAX 190, 
Molecular Devices). Total calcium was calculated from 
standard curves of absorbance versus known concentrations 
of calcium standards run in parallel with the experimental 
samples. Calcium concentration values were normalized by 
substrate area and expressed as µg/cm2.
Statistical analysis
Experiments were conducted in triplicate and repeated at least 
three times. Numerical data were statistically analyzed using 
the standard analysis of variance technique, and statistical 
significance was accepted at P , 0.05.
Results
Stem cell adhesion
The fluorescence images suggest that human MSCs 
attached onto all substrates, as shown in Figure 2. On 
the hydroxyapatite-Ps-PLGA and hydroxyapatite-PLGA 
nanocomposite scaffolds, human MSCs not only attached 
to but also distributed three-dimensionally throughout the 
scaffolds, as shown in Figure 2A and B. In comparison with 
the nanocomposites, much fewer human MSCs adhered onto 
the PLGA control, as shown in Figure 2C. Cell adhesion on 
PLGA-P was not found (image not shown). The human MSCs 
started to spread into the three-dimensional matrix when 
the nanocomposites and PLGA scaffolds degraded. On the 
borosilicate glass reference, the human MSCs attached and 
spread out on the two-dimensional surface and showed well 
pronounced actin stress fibers in Figure 2D.
The adhesion density of human MSC after 6 days of 
standard cell culture was quantified and is summarized in 
Figure 3. Comparing the nanocomposites, human MSC 
adhesion density was greater on the hydroxyapatite-PLGA 
scaffold than on the hydroxyapatite-Ps-PLGA scaffold. The 
human MSC adhesion density was much lower on the PLGA 
and PLGA-P scaffolds compared with the nanocomposites. 
This indicates that incorporation of nanophase hydroxyapatite 
into the PLGA scaffold could enhance human MSC adhesion. 
There was no human MSC adhesion detected on the PLGA-P 
scaffold. The human MSCs adhered to the surface of the glass 
control at a similar density to that of hydroxyapatite-PLGA. 
The larger amount of human MSCs adhered on the glass 
control was expected because the glass surface was plasma-
treated for better cell adhesion.
The increased cell adhesion density after 6 days compared 
with an initial seeding density of 5000 cells/cm2 also indicated 
human MSC proliferation. On the hydroxyapatite-Ps-PLGA 
and hydroxyapatite-PLGA nanocomposites, the average cell 
density was 4708 cells/cm2 and 10,193 cells/cm2, respectively. 
Incorporation of the peptide into the nanocomposites did not 
increase cell adhesion or proliferation. On the PLGA-P and 
PLGA scaffolds, the cell adhesion density was significantly 
lower as compared with that of the nanocomposites. There 
were no detectable cells on the PLGA-P scaffold. On the 
bioactive glass control, the average density of human MSC 
increased to 8508 cells/cm2 after 6 days of culture, which 
was about 1.7 times that of the initial seeding density of 
human MSC.
Stem cell osteogenic differentiation
Alkaline phosphatase activity of the human MSC on the scaf-
folds of interest after 40 days of culture was quantified, as shown 
in Figure 4A. When comparing hydroxyapatite-Ps-PLGA with 
hydroxyapatite-PLGA, although the average alkaline phos-
phatase activity of the human MSC on the hydroxyapatite-Ps-
PLGA was greater than on hydroxyapatite-PLGA, statistical 
significance was not detected between the nanocomposites 
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with or without the DIF-7c peptide. Similarly, there was no 
statistically significant increase in the alkaline phosphatase 
activity of human MSC cultured with hydroxyapatite-Ps as 
compared with hydroxyapatite without the DIF-7c peptide. 
The incorporation of nano-hydroxyapatite or hydroxyapatite-Ps 
in PLGA slightly increased the average alkaline phosphatase 
activity of  human MSC when compared with PLGA alone, but 
this was not statistically significant. There was no statistically 
significant difference in the alkaline phosphatase activity of 
human MSC when hydroxyapatite-Ps was dispersed in the 
PLGA or when it was used alone. The alkaline phosphatase 
activity of human MSC was very similar on the PLGA-P and 
PLGA scaffolds, and there were no statistically significant dif-
ferences. When the DIF-7c peptide was directly injected into 
culture media, the average alkaline phosphatase activity of 
human MSC was slightly greater than the glass and polystyrene 
tissue culture plate (PSTC) references, but the difference was 
not statistically significant. To determine the human MSC osteo-
genic differentiation further, calcium deposition was quantified 
in conjunction with alkaline phosphatase activity.
Calcium deposition by human MSC is an important 
indicator of osteogenic differentiation. Calcium deposition 
per area of the scaffolds after 40 days of culture is shown in 
Figure 4B. No statistically significant difference in calcium 
deposition was detected between hydroxyapatite-Ps-PLGA 
and hydroxyapatite-PLGA. Similarly, the calcium deposition 
results did not show any statistically significant difference 
between hydroxyapatite-Ps and hydroxyapatite. Although 
the average calcium deposition per area was greater on the 
nanocomposites than on the nano-hydroxyapatite, it was 
A B
CD
500 µm
500 µm 500 µm
500 µm
Figure 2 Fluorescence images of human MSC adhesion on (A) HA-Ps-PLgA, (B) HA-PLgA, (C) PLgA, and (D) glass after 6 days of culture.
Notes: Scale bar = 500 µm. green stains, F-actin cytoskeleton. Blue stains, nucleus of human MSC.
Abbreviations: HA, hydroxyapatite; PLgA, polylactide-co-glycolide; P, peptide; MSC, mesenchymal stem cells; Ps, peptide loaded by aminosilane chemistry.
14000
12000
10000
8000
6000
4000
2000
Glass
PLGA
PLGA-P
HA-PLGA
HA-Ps-PLGA
h
M
S
C
 
a
d
h
e
s
i
o
n
 
d
e
n
s
i
t
y
(
c
e
l
l
/
c
m
2
)
0
* *
* * *
**
Figure 3 Human MSC (hMSC) adhesion density was calculated as cells per centimeter 
squared on the scaffolds of interest and controls.
Notes: Data are presented as the mean ± standard error of the mean (n = 3). *P , 0.05 
compared with HA-Ps-PLgA and **P , 0.05 compared with PLgA-P and PLgA.
Abbreviations: HA, hydroxyapatite; PLgA, polylactide-co-glycolide; DIF-7c, bone 
morphogenetic protein (BMP-7)-derived short peptide; P, peptide; Ps, peptide loaded 
by aminosilane chemistry.
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not statistically significant. For the PLGA-P and PLGA 
scaffolds, there was no detectable calcium deposition. When 
the DIF-7c peptide was directly injected into the cell culture 
media, the calcium deposition per area was similar to that of 
nano-hydroxyapatite. This indicates that the effects of nano-
hydroxyapatite on osteogenic differentiation of human MSC 
were similar to that of the peptide. The nano-hydroxyapatite-
containing materials, including hydroxyapatite-Ps-PLGA, 
hydroxyapatite-PLGA, hydroxyapatite-Ps, and hydroxy-
apatite, have demonstrated very similar or slightly greater 
calcium deposition when compared with the peptide 
delivered by direct injection, and they showed much greater 
calcium deposition than PLGA and PLGA-P. Calcium deposi-
tion on the nanocomposites with or without peptide, on the 
nano-hydroxyapatite with or without peptide, and under 
direct injection of DIF-7c peptide was much greater than on 
the glass and PSTC references. The human MSCs deposited 
more calcium on the glass than on the PSTC plate.
Discussion
Nanomaterials have unique advantages for tissue engineering and 
drug delivery applications due to their biomimetic characteristics 
and unique biological and mechanical properties. Due to their 
smaller size, the BMP-7 derived short functional peptide, DIF-7c, 
can maintain bioactivity for a longer period in comparison with 
the large BMP-7 protein. The results of this study demonstrated 
that nanophase hydroxyapatite and nanocomposites (nano-
hydroxyapatite in PLGA composites) can induce osteogenic 
differentiation of human MSC, similar to DIF-7c peptide.
Human MSC adhesion
Nanocomposites improved human MSC adhesion as com-
pared with polymer scaffolds. Specifically, there was a higher 
human MSC attachment on both hydroxyapatite-Ps-PLGA 
and hydroxyapatite-PLGA scaffolds than on PLGA. PLGA 
showed less human MSC adhesion due to its inherent material 
properties and its acidic degradation products.29 When PLGA 
degrades, the degradation products, lactic acid and glycolic 
acid, increase the local pH, which has adverse effects on 
human MSC adhesion and proliferation.30 It has been reported 
that nanophase hydroxyapatite promoted osteoblast adhesion 
and long-term function.31,32 Moreover, nano-hydroxyapatite 
can positively mediate and slow down the degradation of 
PLGA scaffolds because the presence of nano-hydroxyapatite 
in the PLGA matrix interferes with water and oligomer dif-
fusion in and out of the scaffolds. Therefore, as expected, 
human MSC adhesion increased when nano-hydroxyapatite 
was dispersed in PLGA.
However, incorporation of the DIF-7c peptide into the 
scaffolds did not increase human MSC adhesion. For example, 
the cell adhesion density on hydroxyapatite-Ps-PLGA was 
lower than on hydroxyapatite-PLGA. Two factors, ie, surface 
morphology and binding affinity, were speculated to affect 
human MSC adhesion. Scanning electron micrographs of the 
hydroxyapatite-PLGA and hydroxyapatite-Ps-PLGA showed 
that they have different surface morphologies (Figure 1).2,25 
Specifically, the hydroxyapatite-PLGA contained more notice-
able nanofeatures, whereas the hydroxyapatite-Ps-PLGA had 
a relatively smoother surface. These nanofeatures can enhance 
human MSC adhesion, and this might explain why greater 
human MSC adhesion was observed on hydroxyapatite-
PLGA than on hydroxyapatite-Ps-PLGA. BMPs have knuckle 
epitopes that are thought to bind to specific BMP receptors in 
the cell membrane.33 The knuckle epitope of BMP-7 contains 
20 amino acids (TVPKPCCAPTQLNAISVLYF); however, 
the DIF-7c peptide only contains seven end amino acids of the 
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Figure 4 Osteogenic differentiation of human MSCs was characterized by (A) ALP activity and (B) calcium deposition. The human MSCs were cultured with the materials 
as listed in the column.
Notes: Data are presented as the mean ± standard error of the mean (n = 3). No statistical difference was found for ALP activity. For calcium deposition, *P , 0.05 compared 
with glass and PSTC (8 and 9), **P , 0.05 compared with PLgA-P and PLgA (5 and 6), and #P , 0.05 compared with DIF-7c peptide (7).
Abbreviations: ALP, alkaline phosphatase; HA, hydroxyapatite; PLgA, polylactide-co-glycolide; P, peptide; MSC, mesenchymal stem cells; DIF-7c, bone morphogenetic 
protein (BMP-7)-derived short peptide; Ps, peptide loaded by aminosilane chemistry.
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knuckle epitope (CKAISVLYFDDS).33 The DIF-7c peptide 
contained an incomplete knuckle epitope, which might have 
decreased the binding affinity. Similarly, previous research 
showed that there was no significant increase in osteoblast 
adhesion in the presence of the BMP-7 short peptide C 
(AISVLYFDDS).17 Both surface morphology and binding 
affinity may have contributed to the significant decrease of 
human MSC adhesion density on hydroxyapatite-Ps-PLGA as 
compared with the hydroxyapatite-PLGA nanocomposite.
Osteogenic differentiation of human MSC
Osteoinductive biomaterials could stimulate stem cells to 
differentiate towards the osteogenic pathway. Both alkaline 
phosphatase activity and calcium deposition were important 
factors to determine the osteogenic differentiation of human 
MSC. Calcium deposition by human MSC increased in the 
presence of nano-hydroxyapatite and nano-hydroxyapatite-
PLGA composites and when the DIF-7c peptide was directly 
injected into the media. Additionally, no significant difference 
in calcium deposition was found between nano-hydroxyapatite 
with or without DIF-7c peptide and between the nanocom-
posites with or without DIF-7c peptide. This indicates that 
the effects of nano-hydroxyapatite on the osteogenic dif-
ferentiation of human MSC are well pronounced and nano-
hydroxyapatite can enhance osteogenesis even in the absence 
of the peptide. Previous studies on nano-hydroxyapatite 
showed similar results. For example, enhanced calcium depo-
sition by osteoblasts was observed on nano-hydroxyapatite 
in comparison with micron-hydroxyapatite.22,31
The results of this study also indicate that incorporation 
of nano-hydroxyapatite into nanocomposite scaffolds could 
promote both adhesion and osteogenic differentiation of 
human MSC. DIF-7c peptide can promote osteogenic 
calcium deposition when directly injected. Therefore, the 
applications of nano-hydroxyapatite and nano-hydroxyapatite 
in polymer composites are promising alternatives in directing 
the functions of human MSC.
Conclusion
Nanocomposites not only improved adhesion of human 
MSC but also promoted their osteogenic differentiation. 
Incorporation of nano-hydroxyapatite within bioabsorbable 
PLGA scaffolds played an important role in promoting human 
MSC adhesion and differentiation. Direct injection of DIF-7c 
peptide into the culture media resulted in a similar calcium 
deposition level as compared to the nano-hydroxyapatite 
and nanocomposites, which was greater than the glass and 
PSTC references. However, DIF-7c peptide functionalization 
to nano-hydroxyapatite and into nanocomposites did not 
show any significant effect in promoting adhesion and 
human MSC osteogenic differentiation when compared with 
nano-hydroxyapatite and nanocomposites without peptide. 
When both the nano-hydroxyapatite and the DIF-7c peptide 
are present in human MSC culture, the enhancing effects 
of nano-hydroxyapatite on the osteogenic differentiation 
of human MSC were more clearly pronounced than the 
DIF-7c peptide. It is believed that the effects of the nano-
hydroxyapatite may overshadow any effect that the peptide 
may have on differentiation. The nanocomposites demon-
strated promising in vitro results in controlling osteogenic 
differentiation of human MSC without the help of the peptide. 
As nano-hydroxyapatite-PLGA composites could promote 
new bone growth without using the expensive BMPs or 
BMP-derived peptides, their effects on human MSC and 
bone tissue regeneration should be further studied in vivo 
for clinical translation.
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